[
  {
    "ts": null,
    "headline": "3 High-Yield Dividend Stocks Perfect For Retirees",
    "summary": "What does a successful retirement look like? If it means financial security through steady income sources, then you can get there with the help of high-yield dividend stocks. Since retirement is supposed to be a marathon and not a sprint, today we’ll be on the lookout for crown jewel dividend stocks — the best of ... 3 High-Yield Dividend Stocks Perfect For Retirees",
    "url": "https://finnhub.io/api/news?id=ea53103fd948c1a152aa65a96942ec0a65cd94cf483c25786d3a5d48785c3568",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770410256,
      "headline": "3 High-Yield Dividend Stocks Perfect For Retirees",
      "id": 138379641,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "What does a successful retirement look like? If it means financial security through steady income sources, then you can get there with the help of high-yield dividend stocks. Since retirement is supposed to be a marathon and not a sprint, today we’ll be on the lookout for crown jewel dividend stocks — the best of ... 3 High-Yield Dividend Stocks Perfect For Retirees",
      "url": "https://finnhub.io/api/news?id=ea53103fd948c1a152aa65a96942ec0a65cd94cf483c25786d3a5d48785c3568"
    }
  },
  {
    "ts": null,
    "headline": "3 Healthcare Stocks Paying the Highest Dividends of 2026",
    "summary": "Which of the highest-yielding healthcare stocks are value traps or golden opportunities?",
    "url": "https://finnhub.io/api/news?id=6552d8a5012df77d2c2a3e161a090fbff9e883cf989bc0991f7187851b18906e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770410100,
      "headline": "3 Healthcare Stocks Paying the Highest Dividends of 2026",
      "id": 138379671,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Which of the highest-yielding healthcare stocks are value traps or golden opportunities?",
      "url": "https://finnhub.io/api/news?id=6552d8a5012df77d2c2a3e161a090fbff9e883cf989bc0991f7187851b18906e"
    }
  },
  {
    "ts": null,
    "headline": "Unusual Options Activity Alert: 3 Stocks Setting Up for Major Profit Potential",
    "summary": "Volatility returned to markets yesterday, triggering a tech rout. Among the unusually active options on Thursday were 278 calls and puts with Vol/OI ratios of 15 or higher. Among them, these 3 stocks offer options investors significant profit potential. Volatility returned to markets yesterday, triggering a tech rout. Among the unusually active options on Thursday were 278 calls and puts with Vol/OI ratios of 15 or higher. Among them, these 3 stocks offer options investors significant profit pot",
    "url": "https://finnhub.io/api/news?id=0c3ce0dff43528822433b0cd4fc875a820a576c41b8943f60817b46acfa36e4b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770402901,
      "headline": "Unusual Options Activity Alert: 3 Stocks Setting Up for Major Profit Potential",
      "id": 138379561,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Volatility returned to markets yesterday, triggering a tech rout. Among the unusually active options on Thursday were 278 calls and puts with Vol/OI ratios of 15 or higher. Among them, these 3 stocks offer options investors significant profit potential. Volatility returned to markets yesterday, triggering a tech rout. Among the unusually active options on Thursday were 278 calls and puts with Vol/OI ratios of 15 or higher. Among them, these 3 stocks offer options investors significant profit pot",
      "url": "https://finnhub.io/api/news?id=0c3ce0dff43528822433b0cd4fc875a820a576c41b8943f60817b46acfa36e4b"
    }
  },
  {
    "ts": null,
    "headline": "TrumpRx launches to slash drug prices for cash-paying US patients",
    "summary": "Medications, including obesity blockbusters Wegovy and Zepbound, are available on the site.",
    "url": "https://finnhub.io/api/news?id=d6e7dbc53480da50925cf5a9f28b71effdc7e2cc0e2bc791198412c3a166923e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770397082,
      "headline": "TrumpRx launches to slash drug prices for cash-paying US patients",
      "id": 138376806,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Medications, including obesity blockbusters Wegovy and Zepbound, are available on the site.",
      "url": "https://finnhub.io/api/news?id=d6e7dbc53480da50925cf5a9f28b71effdc7e2cc0e2bc791198412c3a166923e"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb: A Dividend Gem With Hidden Upside In 2026",
    "summary": "Bristol-Myers Squibb is upgraded to Buy as its growth portfolio now offsets legacy declines, validating a bullish contrarian thesis. Read the latest analysis on the stock here.",
    "url": "https://finnhub.io/api/news?id=598df7049377e0fe4c94065e6eabf54853a35b89d0257c8ec8a6dd09bab40b87",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770395977,
      "headline": "Bristol-Myers Squibb: A Dividend Gem With Hidden Upside In 2026",
      "id": 138379417,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2252188756/image_2252188756.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibb is upgraded to Buy as its growth portfolio now offsets legacy declines, validating a bullish contrarian thesis. Read the latest analysis on the stock here.",
      "url": "https://finnhub.io/api/news?id=598df7049377e0fe4c94065e6eabf54853a35b89d0257c8ec8a6dd09bab40b87"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Bets Big on Obesity and Oncology With 2026 Pipeline Push",
    "summary": "PFE is betting on obesity and oncology in 2026, lining up 20 pivotal studies after $9B in 2025 M&A.",
    "url": "https://finnhub.io/api/news?id=be58eb620982563eb1157d3e8cc281873da85c5a40b01bbdcb619fd5233daad0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770393960,
      "headline": "Pfizer Bets Big on Obesity and Oncology With 2026 Pipeline Push",
      "id": 138376809,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "PFE is betting on obesity and oncology in 2026, lining up 20 pivotal studies after $9B in 2025 M&A.",
      "url": "https://finnhub.io/api/news?id=be58eb620982563eb1157d3e8cc281873da85c5a40b01bbdcb619fd5233daad0"
    }
  },
  {
    "ts": null,
    "headline": "China Biotech Lights Up. U.S. Stocks Prepare For A New Powerhouse.",
    "summary": "U.S.-based biotech stocks are closely watching the China's rapid advance into the biotech field. Will they withstand the rivalry?",
    "url": "https://finnhub.io/api/news?id=bf9fd4086cefba09a2c9616f9982f188dd4aa1ce3b7402fe5ec75ef2c5ac092b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770382821,
      "headline": "China Biotech Lights Up. U.S. Stocks Prepare For A New Powerhouse.",
      "id": 138374408,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "U.S.-based biotech stocks are closely watching the China's rapid advance into the biotech field. Will they withstand the rivalry?",
      "url": "https://finnhub.io/api/news?id=bf9fd4086cefba09a2c9616f9982f188dd4aa1ce3b7402fe5ec75ef2c5ac092b"
    }
  },
  {
    "ts": null,
    "headline": "5 High-Yield Stocks (6%-8%) Every Retiree Should Consider Now",
    "summary": "These five quality stocks come with at least a 6% dividend and are likely to raise their dividends year in and year out.",
    "url": "https://finnhub.io/api/news?id=20201b9c7c5f2ea8ba9c0f6ecb44e9044d32b27be87bab37f30c135a18577879",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770381917,
      "headline": "5 High-Yield Stocks (6%-8%) Every Retiree Should Consider Now",
      "id": 138374452,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "These five quality stocks come with at least a 6% dividend and are likely to raise their dividends year in and year out.",
      "url": "https://finnhub.io/api/news?id=20201b9c7c5f2ea8ba9c0f6ecb44e9044d32b27be87bab37f30c135a18577879"
    }
  },
  {
    "ts": null,
    "headline": "White House’s online service for drug sales debuts with limited impact on prices",
    "summary": "Select products from Pfizer, Eli Lilly and others will be sold at a discount, although the lower costs won’t be felt by many Americans whose medications are covered by insurance.",
    "url": "https://finnhub.io/api/news?id=9848a56c7fffd6e2975f109c5718388239a7e1122dfb3baf999ba965a90015d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770379680,
      "headline": "White House’s online service for drug sales debuts with limited impact on prices",
      "id": 138376812,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Select products from Pfizer, Eli Lilly and others will be sold at a discount, although the lower costs won’t be felt by many Americans whose medications are covered by insurance.",
      "url": "https://finnhub.io/api/news?id=9848a56c7fffd6e2975f109c5718388239a7e1122dfb3baf999ba965a90015d2"
    }
  },
  {
    "ts": null,
    "headline": "Delonix Bioworks Announces IND Clearance for DX-104, a Novel Engineered MenB OMV Vaccine Candidate, in China and Australia",
    "summary": "Delonix Bioworks, a clinical-stage biotechnology company developing next-generation bacterial vaccines, recently announced that its Group B meningococcal (MenB) vaccine candidate, DX-104, has received Investigational New Drug (IND) clearance from China's National Medical Products Administration (NMPA). This follows the successful completion of Clinical Trial Notification (CTN) procedures and ethics committee approval in Australia in January 2026. Delonix plans to initiate Phase I clinical trials",
    "url": "https://finnhub.io/api/news?id=7f28807bb278c3f876bc4fdd8d8e5e89943e871574748d5d165e686da6a52e98",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770379200,
      "headline": "Delonix Bioworks Announces IND Clearance for DX-104, a Novel Engineered MenB OMV Vaccine Candidate, in China and Australia",
      "id": 138374471,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Delonix Bioworks, a clinical-stage biotechnology company developing next-generation bacterial vaccines, recently announced that its Group B meningococcal (MenB) vaccine candidate, DX-104, has received Investigational New Drug (IND) clearance from China's National Medical Products Administration (NMPA). This follows the successful completion of Clinical Trial Notification (CTN) procedures and ethics committee approval in Australia in January 2026. Delonix plans to initiate Phase I clinical trials",
      "url": "https://finnhub.io/api/news?id=7f28807bb278c3f876bc4fdd8d8e5e89943e871574748d5d165e686da6a52e98"
    }
  },
  {
    "ts": null,
    "headline": "FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need",
    "summary": "NEW YORK, February 06, 2026--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company’s supplemental Biologics License Application (sBLA) for HYMPAVZI® (marstacimab) to expand the approved indication to include the treatment of hemophilia A or B patients 6 years and older with inhibitors, and pediatric patients (ages 6 to 11) with hemophilia A or B without inhibitors. In the U.S., HYMPAVZI is currently appro",
    "url": "https://finnhub.io/api/news?id=287f04a88b604889e7e0ba8a98c5d5427ff5224db06eac44f39fcb3a3288f4f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770378300,
      "headline": "FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need",
      "id": 138373618,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, February 06, 2026--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company’s supplemental Biologics License Application (sBLA) for HYMPAVZI® (marstacimab) to expand the approved indication to include the treatment of hemophilia A or B patients 6 years and older with inhibitors, and pediatric patients (ages 6 to 11) with hemophilia A or B without inhibitors. In the U.S., HYMPAVZI is currently appro",
      "url": "https://finnhub.io/api/news?id=287f04a88b604889e7e0ba8a98c5d5427ff5224db06eac44f39fcb3a3288f4f2"
    }
  },
  {
    "ts": null,
    "headline": "US President Launches TrumpRx.gov to Offer Branded Drugs at Discounted Prices",
    "summary": "US President Donald Trump introduced a platform called TrumpRx.gov on Thursday to lower drug prices,",
    "url": "https://finnhub.io/api/news?id=104799ba3490e9c0f0b165231d8fc9e3b74da11206a7cde9a86f3b9d9d25f837",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770371881,
      "headline": "US President Launches TrumpRx.gov to Offer Branded Drugs at Discounted Prices",
      "id": 138373574,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "US President Donald Trump introduced a platform called TrumpRx.gov on Thursday to lower drug prices,",
      "url": "https://finnhub.io/api/news?id=104799ba3490e9c0f0b165231d8fc9e3b74da11206a7cde9a86f3b9d9d25f837"
    }
  },
  {
    "ts": null,
    "headline": "14 Ideal 'Safer' Dividend Buys From 29 Of 69 February Graham Value All-Stars (GVAS)",
    "summary": "14 Ideal 'Safer' Dividend Buys From 29 Of 69 February Graham Value All-Stars (GVAS)",
    "url": "https://finnhub.io/api/news?id=2a92dc987fd4f872e8a00e76f5432f91f709bbe3b44d46373182ac4ddb78bd50",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770362709,
      "headline": "14 Ideal 'Safer' Dividend Buys From 29 Of 69 February Graham Value All-Stars (GVAS)",
      "id": 138373893,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=2a92dc987fd4f872e8a00e76f5432f91f709bbe3b44d46373182ac4ddb78bd50"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer (PFE) Pricing Reflect Its Prospects After Reshaping Portfolio And Covid Outlook?",
    "summary": "If you are wondering whether Pfizer's current share price still reflects its long term potential, this article will help you unpack what the market might be implying about its value. Pfizer's share price last closed at US$26.49, with returns of 1.5% over the past week, 4.2% over the past month, 5.2% year to date, 10.0% over one year, a 26.7% decline over three years and a 1.2% decline over five years. Recent news coverage has focused on Pfizer's efforts to reshape its product portfolio and...",
    "url": "https://finnhub.io/api/news?id=1e142b7bc9296864f74f175d9175ee17a9ecc69a95676f9527ce18c5d70455dc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770347335,
      "headline": "Is Pfizer (PFE) Pricing Reflect Its Prospects After Reshaping Portfolio And Covid Outlook?",
      "id": 138371235,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "If you are wondering whether Pfizer's current share price still reflects its long term potential, this article will help you unpack what the market might be implying about its value. Pfizer's share price last closed at US$26.49, with returns of 1.5% over the past week, 4.2% over the past month, 5.2% year to date, 10.0% over one year, a 26.7% decline over three years and a 1.2% decline over five years. Recent news coverage has focused on Pfizer's efforts to reshape its product portfolio and...",
      "url": "https://finnhub.io/api/news?id=1e142b7bc9296864f74f175d9175ee17a9ecc69a95676f9527ce18c5d70455dc"
    }
  },
  {
    "ts": null,
    "headline": "Adaptive Biotechnologies Q4 Earnings Call Highlights",
    "summary": "Adaptive Biotechnologies (NASDAQ:ADPT) executives said the company delivered “remarkable” performance in 2025, driven by sharp growth and improving profitability in its minimal residual disease (MRD) franchise and early monetization steps in its Immune Medicine (IM) data platform. On the company’s",
    "url": "https://finnhub.io/api/news?id=eba2f5712bc9c97dde9ad3b1f532fa490c781d20aef630bcb8f01cc6184ac89e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770339983,
      "headline": "Adaptive Biotechnologies Q4 Earnings Call Highlights",
      "id": 138370702,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Adaptive Biotechnologies (NASDAQ:ADPT) executives said the company delivered “remarkable” performance in 2025, driven by sharp growth and improving profitability in its minimal residual disease (MRD) franchise and early monetization steps in its Immune Medicine (IM) data platform. On the company’s",
      "url": "https://finnhub.io/api/news?id=eba2f5712bc9c97dde9ad3b1f532fa490c781d20aef630bcb8f01cc6184ac89e"
    }
  },
  {
    "ts": null,
    "headline": "Trump Touts Drug Cost Savings as He Launches TrumpRx Website",
    "summary": "“Starting tonight, dozens of the most commonly used prescription drugs will be available at dramatic discounts for all consumers through a new website, TrumpRx.gov,” Trump said at a White House event Thursday to hail the new effort.  The administration has touted its efforts to lower the cost of drugs, including by negotiating agreements with more than a dozen of the world’s largest pharmaceutical companies, including Eli Lilly & Co., Novo Nordisk A/S and Pfizer Inc., often in exchange for a reduction in threatened tariffs.",
    "url": "https://finnhub.io/api/news?id=c496ddde896a4d1d2328e83f71a269d47448c874a6e4923a97f8eebaa6565d44",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770339419,
      "headline": "Trump Touts Drug Cost Savings as He Launches TrumpRx Website",
      "id": 138376813,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "“Starting tonight, dozens of the most commonly used prescription drugs will be available at dramatic discounts for all consumers through a new website, TrumpRx.gov,” Trump said at a White House event Thursday to hail the new effort.  The administration has touted its efforts to lower the cost of drugs, including by negotiating agreements with more than a dozen of the world’s largest pharmaceutical companies, including Eli Lilly & Co., Novo Nordisk A/S and Pfizer Inc., often in exchange for a reduction in threatened tariffs.",
      "url": "https://finnhub.io/api/news?id=c496ddde896a4d1d2328e83f71a269d47448c874a6e4923a97f8eebaa6565d44"
    }
  },
  {
    "ts": null,
    "headline": "GoodRx Powers Pricing for Leading Brand Medications on TrumpRx",
    "summary": "SANTA MONICA, Calif., February 06, 2026--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that it is a key integration partner for pharmaceutical companies offering discounted cash prices on TrumpRx.",
    "url": "https://finnhub.io/api/news?id=96b4332d63d68a79590d1ade0bea04c241af5cb152ad41f9861a55d17eb663e7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770338640,
      "headline": "GoodRx Powers Pricing for Leading Brand Medications on TrumpRx",
      "id": 138370703,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "SANTA MONICA, Calif., February 06, 2026--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that it is a key integration partner for pharmaceutical companies offering discounted cash prices on TrumpRx.",
      "url": "https://finnhub.io/api/news?id=96b4332d63d68a79590d1ade0bea04c241af5cb152ad41f9861a55d17eb663e7"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans",
    "summary": "NEW YORK, February 06, 2026--Pfizer Inc. (NYSE: PFE) today announced the launch of its program on TrumpRx, making innovative medicines more affordable and accessible to millions of Americans. Starting today, the program provides Americans a wide range of more than 30 medicines at a significant discount off list prices. This effort is part of Pfizer’s broader landmark Most Favored Nation (MFN) agreement with the U.S. government enabling patients to pay lower prices for their prescription medicine",
    "url": "https://finnhub.io/api/news?id=88eccc511da90d1f0811f2943a3ab05b3646e307c1e25133df4460bff8de11d6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770336540,
      "headline": "Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans",
      "id": 138370704,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, February 06, 2026--Pfizer Inc. (NYSE: PFE) today announced the launch of its program on TrumpRx, making innovative medicines more affordable and accessible to millions of Americans. Starting today, the program provides Americans a wide range of more than 30 medicines at a significant discount off list prices. This effort is part of Pfizer’s broader landmark Most Favored Nation (MFN) agreement with the U.S. government enabling patients to pay lower prices for their prescription medicine",
      "url": "https://finnhub.io/api/news?id=88eccc511da90d1f0811f2943a3ab05b3646e307c1e25133df4460bff8de11d6"
    }
  }
]